- Home
- STTK vs CPTN Comparison
STTK vs CPTN Comparison
Compare STTK & CPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CPTN
- Stock Information
- Founded
- STTK 2016
- CPTN 2016
- Country
- STTK United States
- CPTN United States
- Employees
- STTK N/A
- CPTN N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CPTN Industrial Machinery/Components
- Sector
- STTK Health Care
- CPTN Industrials
- Exchange
- STTK Nasdaq
- CPTN Nasdaq
- Market Cap
- STTK 59.7M
- CPTN 50.5M
- IPO Year
- STTK 2020
- CPTN N/A
- Fundamental
- Price
- STTK $1.24
- CPTN $3.12
- Analyst Decision
- STTK Hold
- CPTN Hold
- Analyst Count
- STTK 3
- CPTN 2
- Target Price
- STTK $2.00
- CPTN $2.50
- AVG Volume (30 Days)
- STTK 357.1K
- CPTN 11.2K
- Earning Date
- STTK 11-14-2024
- CPTN 11-07-2024
- Dividend Yield
- STTK N/A
- CPTN N/A
- EPS Growth
- STTK N/A
- CPTN N/A
- EPS
- STTK N/A
- CPTN N/A
- Revenue
- STTK $6,435,000.00
- CPTN $17,872,000.00
- Revenue This Year
- STTK $115.09
- CPTN $50.39
- Revenue Next Year
- STTK N/A
- CPTN $48.05
- P/E Ratio
- STTK N/A
- CPTN N/A
- Revenue Growth
- STTK 382.75
- CPTN 84.59
- 52 Week Low
- STTK $1.07
- CPTN $2.38
- 52 Week High
- STTK $11.76
- CPTN $5.20
- Technical
- Relative Strength Index (RSI)
- STTK 38.29
- CPTN 45.65
- Support Level
- STTK $1.14
- CPTN $3.10
- Resistance Level
- STTK $1.56
- CPTN $3.16
- Average True Range (ATR)
- STTK 0.12
- CPTN 0.03
- MACD
- STTK 0.07
- CPTN -0.00
- Stochastic Oscillator
- STTK 24.42
- CPTN 33.33
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About CPTN Cepton Inc.
Cepton Inc provides lidar-based solutions for a range of markets such as automotive, smart cities, smart spaces and smart industrial applications. The company's patented MMT-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.